CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds

SAN DIEGO–(BUSINESS WIRE)–#DMT–CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs. CB Therapeutics’ development of a DMT production process, and its patent application, closely follows the first biosynthetic production of psilocybin in yeast and the patent application for the process.

As in CB Therapeutics’ production of psilocybin, analysis of raw analytical DMT samples have shown the biosynthetic process to be significantly more efficient, of higher purity and less expensive than existing chemical and biosynthetic techniques, extraction from plants or other production methods. These proprietary production processes will support clinical trials for these compounds as therapeutics, and potentially their commercialization.

“We are delighted to achieve this scientific milestone for the production of DMT and its analogs for mental healthcare therapeutic clinical trials. We look forward to manufacturing these molecules to further our mission to treat depressive disorders and addiction as an adjunct to psychotherapy. We continue to advance our research and development for the biosynthetic production of these compounds,” said Dr. Jacob Vogan, CSO at CB Therapeutics.

A key feature of the CB Therapeutics’ production platform is that, in addition to making active natural compounds, the platform uses enzymatic processes to create bio-identical compounds as well as their analogs. These analog compounds are very similar to their natural counterparts and may prove to be more effective, targeted and safer for specific therapeutic purposes. ”We have already successfully produced many analogs for DMT and related molecules using our yeast-based platform,” stated Dr. Vogan.

DMT and other tryptamine-based treatments for depression and addiction could become blockbuster therapeutics if approved by the FDA. Existing treatments for these mental health disorders, some more than forty years old, are generally ineffective, must be taken daily and have significant side effects. New treatments are lacking for these significant mental healthcare needs as these diseases continue to become more prevalent in all populations.

“We continue to advance our collaboration with medical and scientific research institutions who will utilize these compounds exclusively for approved clinical trials and medical research,” said Sher Ali Butt, CEO of CB Therapeutics. ‘We believe our research and development efforts on this promising class of therapeutics will support the scientific effort to meet mankind’s most challenging and unmet medical and social needs.”

About CB Therapeutics

CB Therapeutics, Inc., located in San Diego, California, is a biotechnology company focusing on the innovative production of high value molecules and therapeutic compounds for Neuroscience utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs. These analog compounds may prove to be more effective, targeted and safer for therapeutic purposes.

Contacts

Investor Contact:
Sher Ali Butt
sher@cbthera.com
(510) 875-4698

Media Contact:
Eric Tulin
media@cbthera.com
(310) 600-6825